50

Parnax Lab LtdBOM 506128 Stock Report

Last reporting period 30 Sep, 2023

Updated 12 Nov, 2024

Last price

Market cap $B

0.003

Micro

Exchange

XBOM - Bombay Stock Exchange

506128.BO Stock Analysis

50

Uncovered

Parnax Lab Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

54/100

Moderate score

Market cap $B

0.003

Dividend yield

Shares outstanding

11.49 B

Parnax Lab Ltd. engages in manufacturing and trading of pharmaceuticals and medicinal products. The company is headquartered in Mumbai, Maharashtra and currently employs 12 full-time employees. The company went IPO on 2009-09-15. The firm is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. The company is also focused on the trading of pharmaceuticals and medicinal products. The firm operates through dealing in the pharmaceutical formulations segment. The company is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, highly viscous products, suspensions and others. The Company’s subsidiary is Naxpar Pharma Private Limited.

View Section: Eyestock Rating